Ravidasvir

Drug Profile

Ravidasvir

Alternative Names: ASC-16; BI-238630; C5; PPI-668

Latest Information Update: 22 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator XTL Biopharmaceuticals
  • Developer Ascletis; Drugs for Neglected Diseases Initiative Foundation; Ministry of Public Health (Thailand); Pharco Corporation; Presidio Pharmaceuticals
  • Class Antivirals; Benzimidazoles; Carbamates; Naphthalenes; Pyrrolidines; Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Hepatitis C

Most Recent Events

  • 08 Aug 2017 Ascletis Pharmaceuticals initiates enrolment in a phase I trial in Healthy volunteers (Combination therapy) in China (NCT03288636)
  • 21 Apr 2017 Ravidasvir sub-licensed to Medicines Patent Pool in Russia, Ukraine, Egypt and Iran
  • 01 Feb 2017 Ascletis completes the phase II EVEREST trial in Hepatitis C (Combination therapy; Treatment-naive) in Taiwan (NCT03020095)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top